

Moss Genomics Inc.

Condensed Consolidated Interim Financial Statements
For the periods ended December 31, 2024 and 2023

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Moss Genomics Inc.

Condensed Consolidated Interim Statements of Financial Position

As at December 31, 2024 and June 30, 2024

(Expressed in Canadian dollars)

(Unaudited)

		December 31, 2024	June 30, 2024
	Notes		
ASSETS			
Current assets			
Cash		\$ 1,464	\$ 11,740
Prepaid expenses and deposits		5,000	-
GST receivable		21,324	19,877
Total current assets		27,788	31,617
Equipment and software	4	31,041	41,041
TOTAL ASSETS		\$ 58,829	\$ 72,658
LIABILITIES			
Current liabilities			
Accounts payable and accrued liabilities	6, 9	\$ 87,509	\$ 99,411
Loans payable	7, 9	35,000	-
TOTAL LIABILITIES		122,509	99,411
SHAREHOLDERS' EQUITY (DEFICIENCY)			
Share capital		1,483,230	1,483,230
Share-based payment reserve		135,079	100,188
Accumulated deficit		(1,681,989)	(1,610,171)
TOTAL SHAREHOLDERS' EQUITY (DEFICIENCY)		(63,680)	(26,753)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)		\$ 58,829	\$ 72,658

Nature of operations and going concern (Note 1)

Subsequent events (Note 12)

Approved on behalf of the Board on February 28, 2025:

"Hunter Jordan"

Hunter Jordan, Director

"Joseph De Pinto"

Joseph De Pinto, Director

Moss Genomics Inc.

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

For the Three and Six Months ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

		Three months ended December 31 2024	Three months ended December 31 2023	Six months ended December 31, 2024	Six months ended December 31, 2023
	Notes				
EXPENSES					
Amortization	5	\$ 5,000	\$ 5,000	\$ 10,000	\$ 15,974
Interest expense	7	505	-	732	-
News releases and marketing		2,117	-	2,339	2,606
Office and miscellaneous		217	11,076	497	28,486
Professional fees		10,122	4,304	10,990	26,968
Transfer agent and regulatory fees		5,435	8,226	12,369	11,782
Share-based compensation	8, 9	34,891	-	34,891	-
		58,287	28,606	71,818	85,816
LOSS AND COMPREHENSIVE LOSS		\$ (58,287)	\$ (28,606)	\$ (71,818)	\$ (85,816)
Basic and diluted loss per share		\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average number of shares outstanding – basic and diluted		44,827,000	44,688,957	44,827,000	44,608,421

Moss Genomics Inc.

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency)

(Expressed in Canadian dollars)

(Unaudited)

	Number of shares	Share capital	Share-based payment reserve	Accumulated deficit	Total shareholders' equity (deficiency)
Balance, June 30, 2023	44,527,000	\$ 1,453,230	\$ 100,188	\$ (1,477,134)	\$ 76,284
Exercise of warrants	300,000	30,000	-	-	30,000
Loss and comprehensive loss for the period	-	-	-	(85,816)	(85,816)
Balance, December 31, 2023	44,827,000	\$ 1,483,230	\$ 100,188	\$ (1,562,950)	\$ 20,468
Balance, June 30, 2024	44,827,000	\$ 1,483,230	\$ 100,188	\$ (1,610,171)	\$ (26,753)
Issuance of stock options	-	-	34,891	-	34,891
Loss and comprehensive loss for the period	-	-	-	(71,818)	(71,818)
Balance, December 31, 2024	44,827,000	\$ 1,483,230	\$ 135,079	\$ (1,681,989)	\$ (63,680)

Moss Genomics Inc.

Condensed Consolidated Interim Statements of Cash Flow

For the Six Months ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

	December 31, 2024	December 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss for the period	\$ (71,818)	\$ (85,816)
Items not involving cash:		
Amortization	10,000	15,974
Accrued interest	732	-
Share-based compensation	34,891	-
Changes in non-cash working capital items:		
Prepaid expenses	(5,000)	26,053
GST receivable	(1,447)	(1,953)
Accounts payable and accrued liabilities	(12,634)	23,782
Net cash used in operating activities	(45,276)	(21,960)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from loans	35,000	-
Exercise of warrants	-	30,000
Net cash provided by financing activities	35,000	30,000
Change in cash during the period	(10,276)	8,040
Cash, beginning of the period	11,740	17,587
Cash, end of the period	\$ 1,464	\$ 25,627
Cash paid for interest	\$ -	\$ -
Cash paid for income taxes	\$ -	\$ -

During the periods ended December 31, 2024 and 2023, the Company had no non-cash transactions affecting cash flows from financing or investing activities.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

1. Nature of Operations and Going Concern

Moss Genomics Inc. (the "Company") was incorporated under the British Columbia Business Corporations Act on September 25, 2018. The Company is an emerging consumer genomics company, which offers personalized health, anti-aging and wellness offerings. The Company operates solely within one segment. The Company's head office is located at Suite 907 – 1030 West Georgia Street, Vancouver, British Columbia, V6E 2Y3 and the registered and records office of the Company is located at Suite 2200 – 885 West Georgia Street, Vancouver, British Columbia, V6C 3E8.

On January 19, 2023, the Company received final receipt from the British Columbia Securities Commission of the Company's Long Form Prospectus dated January 19, 2023 and the Company's common shares were listed on the Canadian Securities Exchange ("CSE") under the trading symbol "MOSS".

As at December 31, 2024, the Company had a working capital deficit of \$94,721, and an accumulated deficit of \$1,681,989. While the Company has been successful in securing financings in the past, there can be no assurance that it will be able to continue to do so in the future in order to finance its business operations. As such, the Company's business involves a high degree of risk. Additional funds will be required to enable the Company to pursue its business initiatives and the Company may be unable to obtain such financing at all or on terms which are satisfactory to it. Furthermore, there is no assurance that the Company will be profitable. Management intends to finance operating costs over the next twelve months with loans from directors and companies controlled by directors and/or private placement of common shares. These conditions indicate the existence of a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern. As such, there is no guarantee that the Company may continue to operate into the future with the necessary working capital, and it is a clear risk that the liquidity situation of the Company may not remain adequate in order to continue working with suppliers and meeting its liabilities and financial obligations. Due to this fact, the Company recognizes that there is a significant risk around the sufficiency of cash and cash equivalents both now and looking into the future.

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business. These condensed consolidated interim financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. These adjustments could be material.

2. Basis of Preparation

Statement of Compliance with International Financial Reporting Standards

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting, using accounting policies consistent with the International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). These condensed consolidated interim financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended June 30, 2024, which have been prepared in accordance with IFRS as issued by the IASB, and interpretations of IFRIC.

Basis of Measurement

These condensed consolidated interim financial statements have been prepared on a historical cost basis except for certain financial instruments classified as fair value through profit and loss, which are stated at their fair values. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting and are presented in Canadian dollars unless otherwise specified.

Basis of Consolidation

The condensed consolidated interim financial statements include the accounts of the Company and its wholly owned subsidiaries, Moss Genomics Holdings Inc., and Moss Genomics (US) Inc. Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

3. Material Accounting Policy Information

The accounting policies followed by the Company are set out in Note 3 to the audited consolidated financial statements for the year ended June 30, 2024 and have been consistently followed in the preparation of these condensed consolidated interim financial statements.

4. Significant Accounting Judgements, Estimates and Assumptions

The preparation of the Company's condensed consolidated interim financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical Judgements

Critical judgments exercised in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements are as follows:

i) Going Concern

The assessment of whether the going concern assumption is appropriate requires management to take into account all available information about the future, which is at least twelve months from the end of the reporting period. The Company is aware that material uncertainties related to events or conditions may cast significant doubt upon the Company's ability to continue as a going concern (Note 1).

ii) Income taxes

The Company recognizes deferred tax assets for deductible temporary differences, unused tax losses and other income tax deductions only to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, unused tax losses and other income tax deductions can be utilized. In assessing the probability of realizing the income tax benefits of deductible temporary differences, unused tax losses and other income tax deductions, management makes estimates related to expectations of future taxable income, applicable tax planning opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. The likelihood that tax positions taken will be sustained upon examination by applicable tax authorities is assessed based on individual facts and circumstances of the relevant tax position evaluated in light of all available evidence.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

4. Significant Accounting Judgements, Estimates and Assumptions (continued...)***Estimation Uncertainty***

The following are key assumptions concerning the future and other key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year:

i) Determination of useful lives of equipment and software

Each significant component of equipment and software is depreciated over their estimated useful lives. Estimated useful lives are determined based on current facts and past management experience and take into consideration the anticipated physical life of the asset, existing long-term sales agreements, and contracts, current and forecasted demand, and the potential for technological obsolescence.

ii) Non-monetary, share-based transactions

Estimating the fair value for granted stock options and compensatory warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate model including the expected life of the option or warrant, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

5. Equipment and Software

Equipment and software is carried at cost less accumulated amortization. Details are as follows:

	Equipment	Software	Total
Cost			
Balance, June 30, 2023, 2024, and December 31, 2024	\$ 100,000	\$ 50,705	\$ 150,705
Accumulated amortization			
Balance, June 30, 2023	\$ 38,959	\$ 44,731	\$ 83,690
Amortization	20,000	5,974	25,974
Balance, June 30, 2024	58,959	50,705	109,664
Amortization	10,000	-	10,000
Balance, September 30, 2023	\$ 68,959	\$ 50,705	\$ 119,664
Net book value			
Balance, June 30, 2024	\$ 41,041	\$ -	\$ 41,041
Balance, December 31, 2024	\$ 31,041	\$ -	\$ 31,041

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

6. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities as at December 31, 2024 and June 30, 2024 consist of the following:

	December 31, 2024		June 30, 2024	
Accounts payable (Note 9)	\$	86,777	\$	93,836
Accrued interest (Note 7)		732		-
Accrued expenses		-		5,575
	\$	87,509	\$	99,411

7. Loans Payable

Loans payable and accrued liabilities as at December 31, 2024 and June 30, 2024 consist of the following:

	December 31, 2024		June 30, 2024	
On August 12, 2024, the Company entered into a loan agreement with a shareholder to borrow \$10,000. The amount is unsecured, bears interest at 10% and is due on August 12, 2025 (Note 9).	\$	10,000	\$	-
On August 27, 2024, the Company entered into a loan agreement with a shareholder to borrow \$10,000. The amount is unsecured, bears interest at 10% and is due on August 27, 2025. (Note 9).		10,000		-
On August 29, 2024, the Company entered into a loan agreement with a shareholder to borrow \$10,000. The amount is unsecured, bears interest at 10% and is due on August 29, 2025. (Note 9).		10,000		-
On November 22, 2024, the Company borrowed \$5,000 from a director at the time. This amount is non-interest bearing, unsecured, and due on demand. (Note 9).		5,000		-
Total	\$	35,000	\$	-

During the six month period ended December 31, 2024, the Company accrued \$732 in interest expense on these loans (2023- \$Nil).

As at December 31, 2024, a total of \$732 of interest has been accrued for these loans (June 30, 2024 - \$Nil).

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

8. Share Capital

(a) Authorized

The Company has authorized an unlimited number of common shares without par value.

(b) Issued

As at December 31, 2024, there were 44,827,000 common shares outstanding (June 30, 2024 – 44,827,000).

At December 31, 2024, there were 5,699,250 (June 30, 2024 – 7,599,250) shares held in escrow, 1,899,750 to be released on January 19, 2025, and 1,899,750 every 6 months thereafter, until January 19, 2026, where all remaining shares will be released.

During the six months ended December 31, 2024:

There were no common shares issued during the six months ended December 31, 2024.

During the year ended June 30, 2024:

- On October 30, 2023, 200,000 warrants were exercised into an equivalent number of common shares for gross proceeds of \$20,000.
- On December 6, 2023, 100,000 warrants were exercised into an equivalent number of common shares for gross proceeds of \$10,000.

(c) Stock options

The Company has established a stock option plan (the "Plan"), in which the maximum number of common shares which can be reserved for issuance is 10% of the issued and outstanding common shares of the Company. The terms of the granted options are fixed by the Board and are not to exceed five years. The exercise price of options is determined by the Board, but shall not be less than the market price of the Company's common shares on the grant date. The Board, subject to the policies of the Exchanges, may determine and impose terms upon which each Option will become Vested in respect of Option Shares. Options granted to Consultants performing Investor Relations Activities must vest, at minimum, in stages over twelve months with no more than one-quarter of the Options vesting in any three (3) month period.

During the period ended December 31, 2024, the Company issued 600,000 stock options to directors, officers, and consultants, exercisable at \$0.10 per option, for a period of 5 years. These options were valued at \$34,891 (\$0.0582 per option) using the Black-Scholes Option Pricing Model, with the following assumptions: volatility – 100%, discount rate – 3.05%; dividend rate – 0%; and expected life – 5 years.

The Company did not issue any stock options during the year ended June 30, 2024.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

8. Share Capital (continued...)

(c) Stock options (continued...)

A summary of the continuity of the Company's stock options is as follows:

	Number of options	Weighted average exercise price
Balance, June 30, 2023	1,120,000	\$0.10
Expired	(25,000)	\$0.10
Balance, June 30, 2024	1,095,000	\$0.10
Granted	600,000	\$0.10
Cancelled	(200,000)	\$0.10
Balance, December 31, 2024	1,495,000	\$0.10

The following table summarizes information about the share options outstanding and exercisable at December 31, 2024:

Number of options outstanding	Number of options exercisable	Exercise price	Remaining life (years)	Expiry date
895,000	895,000	\$0.10	3.15	February 22, 2028
600,000	600,000	\$0.10	4.98	December 24, 2029
1,495,000	1,495,000	\$0.10	3.88	

(d) Warrants

A summary of the continuity of the Company's warrants is as follows:

	Number of Warrants	Weighted average exercise price
Balance, June 30, 2023	5,000,000	\$0.10
Exercised	(300,000)	\$0.10
Expired	(4,700,000)	\$0.10
Balance, June 30, 2024 and December 31, 2024	-	-

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

9. Related Party Transactions

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consists of members of the Board and corporate officers, including the Company's Chief Executive Officer and Chief Financial Officer.

During the three and six months ended December 31, 2024, the Company issued 600,000 stock options to directors and officers, resulting in a share-based compensation expense of \$34,891 (2023 - \$Nil).

As at December 31, 2024, included in accounts payable is \$12,325 (June 30, 2024 - \$12,235) owing to the former CEO of the Company.

As at December 31, 2024, included in Loans payable is \$30,000 (June 30, 2024 - \$Nil) owing to various shareholders of the Company, with terms described in Note 7.

As at December 31, 2024, included in loans payable is \$5,000 (June 30, 2024 - \$Nil) owing to a former director of the Company, with terms described in Note 7..

10. Financial Instruments

Fair values

Financial instruments are classified into one of the following categories: fair value through profit and loss ("FVTPL"); amortized cost; and fair value through other comprehensive income ("FVTOCI"). The carrying value of the Company's financial instruments are classified into these categories, as follows:

Financial Instrument	Category	December 31,	
		2024	June 30, 2024
Cash	FVTPL	\$ 1,464	\$ 11,740
Accounts payable and accrued liabilities	Amortized cost	\$ 87,509	\$ 99,411
Loans payable	Amortized cost	\$ 35,000	\$ -

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy based on the degree to which the inputs used to determine the fair value are observable. The three levels of the fair value hierarchy are:

- Level 1 Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.
- Level 2 Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the market place.
- Level 3 Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

10. Financial Instruments (continued...)

Fair values (continued...)

The Company's financial instruments consist of cash, accounts payable and accrued liabilities, and loans payable. Cash is carried at fair value using level 1 inputs. The fair values of accounts payable and accrued liabilities, and loans payable approximate their carrying values, due to their time to maturity

Risk

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

(a) Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by depositing its cash with high credit quality financial institutions. The carrying amount of cash represents the maximum credit exposure, being \$1,464 at December 31, 2024.

(b) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. As at December 31, 2024, the Company did not have sufficient cash on hand to cover its short-term financial liabilities. Subsequent to period end, the Company completed a financing, which provided sufficient capital to cover its short-term liabilities. (Note 12).

As at December 31, 2024, all of the Company's finance liabilities are due in one year or less.

(c) Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and commodity and equity prices. These fluctuations may be significant.

(i) Interest Rate Risk

Interest rate risk is the risk that the fair value or cash flows of a financial instrument will fluctuate because of changes in market interest rates. The exposure to interest rates for the Company is considered minimal, as the Company has no variable interest bearing borrowings.

(ii) Foreign Currency Risk

The Company is exposed to foreign currency risk on fluctuations related to accounts payable and accrued liabilities that are denominated in a foreign currency. As at December 31, 2024 the Company had \$15,488 in accounts payable dominated in US Dollars. A 5% fluctuation in foreign exchange rates between the US Dollar and the Canadian Dollar would result in a change to net and comprehensive loss of approximately \$775. The Company does not hedge its exposure to foreign exchange risk, as it considers this risk to be low.

(iii) Other Price Risk

Other price risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market prices (other than those arising from interest rate and currency risk). As at December 31, 2024, the Company is not exposed to other price risk.

Moss Genomics Inc.

Notes to the Condensed Consolidated Interim Financial Statements

For the Periods ended December 31, 2024 and 2023

(Expressed in Canadian dollars)

(Unaudited)

11. Management of Capital

The Company considers its capital to be comprised of shareholders' equity. The Board does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

In order to carry out the planned activities and pay for administrative costs, the Company may attempt to raise additional amounts of capital through the issuance of shares. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management since incorporation. The Company is not subject to external capital requirements.

12. Subsequent Events

- On January 14, 2025, the Company successfully listed its shares on the Frankfurt Stock Exchange (FSE) under the symbol F73.
- On January 31, 2025, the Company closed a private placement of 2,500,000 common shares at \$0.10 per share, for total gross proceeds of \$250,000. Concurrently, the Company closed the acquisition of 160 Ethereum cryptocurrency in consideration of the issuance of 7,840,000 common shares.
- On January 31, 2025, the Company granted 200,000 stock options to certain directors, officers, and consultants of the Company. Each option is exercisable at \$0.20 for a period of 5 years.